Because our proteomic analysis identified CCL2 to be among the TRAIL-induced factors with a high potential for biological functionality, we hypothesized that stimulation of cancer cell-expressed TRAIL-R may result in CCL2 production by tumor cells and, thereby, facilitate the accumulation of alternatively activated M2-type cells in the tumor microenvironment. This evidence concerns the gene CCL2 and cancer.